Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-10-20Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia [Phase 3]
Phase 3 trial for SAGE-217 in adults with comorbid Major Depressive Disorder and Insomnia was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-10-20Clinical Trial Update: Mobile Mental Health Apps for Suicide Prevention [NA]
Completed clinical trial of mobile mental health apps for suicide prevention; results posted in 2022.
-
FDA approval · 2022-10-18FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved the supplemental application for trazodone hydrochloride from Zydus Lifesciences Limited. This confirms regulatory approval of …
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: A Trial of AXS-05 in Patients With Major Depressive Disorder [Phase 3]
Phase 3 trial results for AXS-05 in major depressive disorder have been completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Open-Label Safety Study of AXS-05 in Subjects With Depression [Phase 3]
Open-label safety study of AXS-05 in subjects with depression completed; results posted in 2022.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-10-05FDA Approved: CITALOPRAM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for citalopram submitted by Torrent Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2022-10-03Clinical Trial Update: A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder [Phase 3]
Phase 3 trial evaluating SAGE-217 (zuranolone) for prevention of relapse in adults with major depressive disorder was terminated; results po…
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) [NA]
Completed clinical trial TIME studied targeted self-management for epilepsy and serious mental illness; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-09-27Clinical Trial Update: Screening Wizard- Phase 2 [NA]
Phase 2 clinical trial update for Screening Wizard investigating depression and suicidal ideation; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) [Phase 3]
Phase 3 pediatric trial updating active reference study of fixed-dose vortioxetine with fluoxetine in children aged 7-11 with major depressi…
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Effectiveness of a Telephone-Delivered Behavioral Treatment to Improve the Quality of Life of Older Adults With HIV [Phase 2, Phase 3]
Phase 2/3 trial assessing a telephone-delivered behavioral treatment to improve quality of life in older adults with HIV and depression; stu…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone [Phase 3]
Phase 3 trial assessing cariprazine as an adjunctive treatment to antidepressants in adults with major depressive disorder who had an inadeq…
-
FDA approval · 2022-09-20FDA Approved: ARIPIPRAZOLE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for ARIPIPRAZOLE by Dr. Reddy's Laboratories Inc. under the ANDA, authorizing a modification to the …
-
CLINICAL_TRIALS trial_result · 2022-09-16Clinical Trial Update: Adapting Behavioral Activation to Technology Platform [NA]
Clinical trial on adapting Behavioral Activation to a technology platform for depression has completed with results posted.
-
FDA approval · 2022-09-15FDA Approved: MIRTAZAPINE — Supplemental Application (Aurolife Pharma LLC)
FDA granted a supplemental approval to Aurolife Pharma LLC for a generic form of mirtazapine, authorizing continued supply of the antidepres…
-
FDA approval · 2022-09-15FDA Approved: MIRTAZAPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for mirtazapine from Sun Pharmaceutical Industries, Inc. (ANDA 076541). The action supports cont…
-
FDA approval · 2022-09-15FDA Approved: MIRTAZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for a generic version of mirtazapine by Mylan Pharmaceuticals, confirming continued approval for maj…
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Zambia Common Elements Treatment Approach Pilot Study [NA]
A pilot study update for the Zambia Common Elements Treatment Approach was terminated; results posted in 2022, investigating treatment for c…
-
CLINICAL_TRIALS trial_result · 2022-09-09Clinical Trial Update: Microbiotherapy in Characterized Depressive Disorder [Phase 2]
Phase 2 clinical trial update for microbiotherapy in characterized depressive disorder is in early status with unspecified results.
-
CLINICAL_TRIALS trial_result · 2022-09-08Clinical Trial Update: A Computer-Assisted CBT Tool to Enhance Fidelity in CBOCs [NA]
A completed clinical trial evaluating a computer-assisted CBT tool to improve treatment fidelity in community-based outpatient clinics for d…
-
CLINICAL_TRIALS research · 2022-09-08Clinical Trial Update: Neurobiological Underpinnings of Placebo Response in Depression [Phase 4]
A Phase 4 clinical trial explored the neurobiological underpinnings of placebo response in patients with depression and has completed.
-
CLINICAL_TRIALS trial_result · 2022-09-08Clinical Trial Update: Ketamine and Epigenetic Aging [Phase 2]
Phase 2 clinical trial update exploring ketamine and epigenetic aging for depression and PTSD.
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Pentoxifylline for Treatment of Resistant Major Depression [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pentoxifylline for treatment of resistant major depression has completed.
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder [Phase 1, Phase 2]
A clinical trial investigating pentoxifylline as an adjunct to citalopram in adults with major depressive disorder has completed phase 1 and…
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Multi-factor Model Constraction for Early Warning and Diagnosis of MDD [Phase 4]
Phase 4 clinical trial update on a multi-factor model for early warning and diagnosis of major depressive disorder and bipolar disorder, inc…